Zobrazeno 1 - 10
of 19
pro vyhledávání: '"André van Maurik"'
Autor:
Xavier Mariette, Francesca Barone, Chiara Baldini, Hendrika Bootsma, Kenneth L. Clark, Salvatore De Vita, David H. Gardner, Robert B. Henderson, Michael Herdman, Karoline Lerang, Prafull Mistry, Raj Punwaney, Raphaele Seror, John Stone, Paul L.A. van Daele, André van Maurik, Nicolas Wisniacki, David A. Roth, Paul Peter Tak
Publikováno v:
JCI Insight, Vol 7, Iss 23 (2022)
BACKGROUND Primary Sjögren’s syndrome (pSS) is characterized by B cell hyperactivity and elevated B-lymphocyte stimulator (BLyS). Anti-BLyS treatment (e.g., belimumab) increases peripheral memory B cells; decreases naive, activated, and plasma B c
Externí odkaz:
https://doaj.org/article/ae87bdd4bc564a1dae2056fee6339f06
Autor:
Timothy R D J Radstake, Joel A G van Roon, Maarten R Hillen, Sofie L M Blokland, Aridaman Pandit, Katia Urso, Emma Koppe, Ana Pinheiro Lopes, Tom Slocombe, André van Maurik
Publikováno v:
RMD Open, Vol 6, Iss 2 (2020)
Externí odkaz:
https://doaj.org/article/566de61c49bb45258f81094aa8bf8f1c
Autor:
Bernie Rubin, Kerry Gairy, Tania Gonzalez-Rivera, David M. Roth, Roger A. Levy, Susan W Burriss, N.L. Fox, Munther Khamashta, André van Maurik, Angela Jones-Leone
Publikováno v:
Lupus
Systemic lupus erythematosus (SLE) is a chronic autoimmune inflammatory disease affecting both adults and children. Belimumab is the only biologic approved for SLE, and the first in a class of drugs known as B-lymphocyte stimulator-specific inhibitor
Autor:
Nicolas Wisniacki, Azeem Saleem, Paul Galette, Coziana Ciurtin, Ruth M. Tarzi, Teresa Fuller, Kathleen Port, Robert L. Janiczek, Davide Lucchesi, Calum Gray, Marius de Groot, Pilar Jimenez-Royo, Anwar R. Tappuni, Michele Bombardieri, Michalis Kostapanos, Mats Bergström, Elena Pontarini, Natasha Jordan, Nirav Ratia, André van Maurik, Neel Patel, Lucy E Kershaw, Graham E. Searle
Publikováno v:
Jimenez-royo, P, Bombardieri, M, Ciurtin, C, Kostapanos, M, Tappuni, A R, Jordan, N, Saleem, A, Fuller, T, Port, K, Pontarini, E, Lucchesi, D, Janiczek, R L, Galette, P, Searle, G E, Patel, N, Kershaw, L, Gray, C, Ratia, N, van Maurik, A, de Groot, M, Wisniacki, N, Bergstrom, M & Tarzi, R 2021, ' Advanced imaging for quantification of abnormalities in the salivary glands of patients with primary Sjögren's Syndrome ', Rheumatology, vol. 60, no. 5, pp. 2396–2408 . https://doi.org/10.1093/rheumatology/keaa624
Rheumatology (Oxford, England)
Rheumatology (Oxford, England)
Objectives To assess non-invasive imaging for detection and quantification of gland structure, inflammation and function in patients with primary Sjogren's syndrome (pSS) using PET-CT with 11C-Methionine (11C-MET; radiolabelled amino acid), and 18F-f
Autor:
Bart O. Roep, Nicolas Wisniacki, Rene J. Mclaughlin, Pieter Gillard, Robert Hilbrands, Frans Gorus, João Joaquim Oliveira, Chantal Mathieu, Antonella Napolitano, André van Maurik, Dave Inman, Bart Keymeulen, Rachel M. Gittelman, Ursule Van de Velde
Publikováno v:
Diabetologia
Aims/hypothesis Numerous clinical studies have investigated the anti-CD3ɛ monoclonal antibody otelixizumab in individuals with type 1 diabetes, but limited progress has been made in identifying the optimal clinical dose with acceptable tolerability
Autor:
Ruth M Barnard, David Inman, Kevin R. Page, Bart Keymeulen, Quentin Leirens, Alexander MacDonald, Antonella Napolitano, Kim Brown, David Lanham, Jonathan Bullman, Minesh Patel, André van Maurik, Enrica Mezzalana, Caroline O. S. Savage, Georgios Vlasakakis, Stefano Zamuner
Publikováno v:
British Journal of Clinical Pharmacology. 85:704-714
Aims This paper describes the pharmacological findings from a study where otelixizumab, an anti-CD3ɛ mAb, was dosed in new onset Type 1 diabetes mellitus (NOT1DM) patients. This is the first time that the full dose-response of an anti-CD3ɛ mAb has
Autor:
Simon M. McHugh, Paul W. Thompson, Frank A Gray, Onajite Kousin-Ezewu, Jenny L Craigen, Disala Fernando, Alasdair Coles, Donggang Su, Joanne Ellis, Keguan Chen, Sara Santos Franco, Joao-Joaquim Oliveira, Kim Brown, Lea Fortunato, André van Maurik, Ann M. Schwartz, Sophie Gisbert, Jiansong Yang, Sara Brett, Bill Davis, Joseph Cheriyan, Andrew Want, Jeffrey Price
Publikováno v:
British Journal of Clinical Pharmacology
Aim Interleukin (IL)-7 signalling modulates T cell activity and is implicated in numerous autoimmune diseases. The present study investigated the safety, pharmacokinetics, target engagement, pharmacodynamics and immunogenicity of GSK2618960, an IL-7
Autor:
Anwar R. Tappuni, Graham Searle, Nicolas Wisniacki, Michele Bombardieri, Mats Bergström, Ruth M. Tarzi, Natasha Jordan, Teresa Fuller, Nirav Ratia, Michalis Kostapanos, Rob Janiczek, Neel Patel, Kathleen Port, Lucy E Kershaw, Paul Galette, Elisa Astorri, Pilar Jimenez-Royo, Saleem Azeem, Marius de Groot, Calum Gray, Coziana Ciurtin, André van Maurik
Publikováno v:
Abstracts Accepted for Publication.
Background: Saliva and tear flow rates and minor salivary gland biopsy are typically used to assess gland function and disease activity in primary Sjogren’s syndrome (pSS); however, these have limitations. Imaging methods can directly visualize and
Autor:
Mark E. McClure, Seerapani Gopaluni, James Wason, Robert B. Henderson, Andre Van Maurik, Caroline C.O. Savage, Charles D. Pusey, Alan D. Salama, Paul A. Lyons, Jacinta Lee, Kim Mynard, David R. Jayne, Rachel B. Jones, on behalf the COMBIVAS investigators
Publikováno v:
Trials, Vol 24, Iss 1, Pp 1-13 (2023)
Abstract Background Sequential B cell-targeted immunotherapy with BAFF antagonism (belimumab) and B cell depletion (rituximab) may enhance B cell targeting in ANCA-associated vasculitis (AAV) through several mechanisms. Methods Study design: COMBIVAS
Externí odkaz:
https://doaj.org/article/de0d5603a4e24992b66dd2efe0d957ae
Autor:
David C. Howe, Clare A. Notley, Shawn D P Ellis, Jenny L. McGovern, André van Maurik, Michael R. Ehrenstein
Publikováno v:
Arthritis & Rheumatology. 66:2694-2705
Objective Limiting the severity of inflammation and promoting its eventual resolution are vital for protecting host tissues both in autoimmunity and chronic infection. The aim of this study was to determine the suitability of repurposing anti-CD3 mon